Business Description
Straumann Holding AG
ISIN : CH1175448666
Total Employee Number:
11,824Compare
Compare
Traded in other countries / regions
STMN.Switzerland0QMV.UKSAUHY.USAQS50.Germany1STMN.ItalySTMN.AustriaSTMN N.Mexico IPO Date
2025-05-05Description
Straumann is a global leader in dental implants and orthodontics solutions. Its portolio includes abutments, clear aligners, biomaterials, and computer-aided design/computer-aided manufacturing equipment. The firm's core products are dental implants, and it controls over one-third of the CHF 6 billion global market. Originally a pure premium implant player, Straumann entered the value market in 2012 with its acquisition of Neodent. Straumann now accounts for almost half of the global premium market and around 15% of the value market. While its premium product catalog is marketed under Straumann, its value brands include Neodent, Anthogyr, and Medentika as well as other local and regional brands.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.81 | |||||
Equity-to-Asset | 0.59 | |||||
Debt-to-Equity | 0.22 | |||||
Debt-to-EBITDA | 0.83 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 8.06 | |||||
Beneish M-Score | -2.69 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 3.9 | |||||
3-Year EBITDA Growth Rate | -2.5 | |||||
3-Year EPS without NRI Growth Rate | -0.4 | |||||
3-Year FCF Growth Rate | 8.5 | |||||
3-Year Book Growth Rate | 5.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 13.64 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 8.86 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 64.07 | |||||
9-Day RSI | 55.6 | |||||
14-Day RSI | 51.95 | |||||
3-1 Month Momentum % | 16.58 | |||||
6-1 Month Momentum % | 6.86 | |||||
12-1 Month Momentum % | 7.92 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.26 | |||||
Quick Ratio | 1.61 | |||||
Cash Ratio | 0.55 | |||||
Days Inventory | 210.96 | |||||
Days Sales Outstanding | 88.01 | |||||
Days Payable | 197.85 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 1.05 | |||||
Dividend Payout Ratio | 0.34 | |||||
3-Year Dividend Growth Rate | 12.1 | |||||
Forward Dividend Yield % | 1.05 | |||||
5-Year Yield-on-Cost % | 1.82 | |||||
Shareholder Yield % | 1.14 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 68.67 | |||||
Operating Margin % | 21.63 | |||||
Net Margin % | 14 | |||||
EBITDA Margin % | 23.26 | |||||
FCF Margin % | 12.84 | |||||
OCF Margin % | 19.83 | |||||
ROE % | 17.04 | |||||
ROA % | 9.92 | |||||
ROIC % | 16.2 | |||||
3-Year ROIIC % | -6.02 | |||||
ROC (Joel Greenblatt) % | 39.74 | |||||
ROCE % | 15.47 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 7 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 41.36 | |||||
Forward PE Ratio | 25.33 | |||||
PE Ratio without NRI | 32.43 | |||||
Shiller PE Ratio | 47.58 | |||||
Price-to-Owner-Earnings | 44.74 | |||||
PEG Ratio | 1.85 | |||||
PS Ratio | 5.81 | |||||
PB Ratio | 6.71 | |||||
Price-to-Tangible-Book | 10.91 | |||||
Price-to-Free-Cash-Flow | 45.22 | |||||
Price-to-Operating-Cash-Flow | 29.27 | |||||
EV-to-EBIT | 34.01 | |||||
EV-to-Forward-EBIT | 22.79 | |||||
EV-to-EBITDA | 25.09 | |||||
EV-to-Forward-EBITDA | 18.85 | |||||
EV-to-Revenue | 5.83 | |||||
EV-to-Forward-Revenue | 5.16 | |||||
EV-to-FCF | 44.18 | |||||
Price-to-GF-Value | 0.81 | |||||
Price-to-Projected-FCF | 2.58 | |||||
Price-to-DCF (Earnings Based) | 1.04 | |||||
Price-to-DCF (FCF Based) | 2.08 | |||||
Price-to-Median-PS-Value | 0.64 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.85 | |||||
Price-to-Graham-Number | 3.96 | |||||
| Price-to-Net-Current-Asset-Value | 152.94 | |||||
Earnings Yield (Greenblatt) % | 2.94 | |||||
FCF Yield % | 2.21 | |||||
Forward Rate of Return (Yacktman) % | 19.54 |
Straumann Holding AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Straumann Holding AG Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-18 10:30 | In 169 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-18 07:00 | In 169 days | ||
| Annual report for 2026 | 2027-02-18 | In 168 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-29 10:30 | In 57 days | ||
| Third quarter earnings results for 2026 | 2026-10-29 | In 56 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-19 10:30 | 98.50 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-08-19 07:00 | 98.50 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-04-29 10:30 | 93.50 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-04-29 07:00 | 93.50 (+0.00%) | ||
| CHF 1.000000 Cash Dividend | 2026-04-21 | 87.00 (-11.22%) |
Show
Entries
Press Release
| Subject | Date | ||
|---|---|---|---|
| Bay Materials Obtains Patents to Protect Innovative Clear-Aligner Material Zenduraâ„¢ FLX | 2021-01-05 | ||
| Straumann Becomes a Strategic Investor in Dental Monitoring | 2018-04-12 |
Articles on Straumann Holding AG
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers